Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
NCT04720664
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class
Stopped
Lack of efficacy
Conditions
Breast Cancer
Metastatic Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Interventions
DRUG:
SM-88
Sponsor
Georgetown University
Collaborators
[object Object]